biostudies-literatureUnknown4(5)Tarantelli CCopanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of targeted agents. Here, we searched for novel copanlisib-based combinations. Copanlisib was tested as a single agent, in combination with an additional 17 drugs in 26 cell lines derived from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and T-cell lymphomas. In vivo experiments, transcriptome analyses, and immunoblotting experiments were also performed. Copanlisib as a single agent showed in vitro dose-dependent antitumor activity in the vast majority of the models. Combination screeninBlood advances819-829https://www.ebi.ac.uk/biostudies/studies/S-EPMC7065481biostudies-literatureCopanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.PMC7065481Sturz AKwee IRossi DCascione LSpriano FScalise LLiu NArribas AJBertoni FPolitz OSperl CGritti GStathis ATarantelli CMargheriti FZucca ERinaldi AJourdan TLange MGaudio EBerthold MfalseCopanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of targeted agents. Here, we searched for novel copanlisib-based combinations. Copanlisib was tested as a single agent, in combination with an additional 17 drugs in 26 cell lines derived from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and T-cell lymphomas. In vivo experiments, transcriptome analyses, and immunoblotting experiments were also performed. Copanlisib as a single agent showed in vitro dose-dependent antitumor activity in the vast majority of the models. Combination screenin2020-01-01T00:00:00Z2020 Mar2026-04-30T22:15:24.516Z2025-04-06T01:56:54.457ZS-EPMC70654813212614210.1182/bloodadvances.2019000844